Cellular Goods Share Price (CBX)

Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Cellular Goods Plc LSE:CBX London Ordinary Share GB00BK964W87 ORD GBP0.001
  Price Change % Change Share Price Shares Traded Last Trade
  -0.05 -4.17% 1.15 1,078,461 09:21:48
Bid Price Offer Price High Price Low Price Open Price
1.05 1.25 1.20 1.15 1.20
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Personal Goods 6
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:05 O 250,000 1.05 GBX
Related Shares
Burberry (BRBY), Pz Cussons (PZC), Pittards (PTD), Eve Sleep (EVE)

Cellular Goods (CBX) Latest News

Cellular Goods News

Date Time Source Headline
20/6/202211:44ALNCIN BRIEF: Cellular Goods wants CBD advertising on social media
20/6/202207:00RNSNONCellular Goods PLC Launch of CBG and CBD petition
30/5/202211:38ALNCIN BRIEF: Cellular Goods interim loss widens; expects slower growth
30/5/202207:00UKREGCellular Goods PLC Interim results
20/5/202207:01UKREGCellular Goods PLC TR-1: Standard notification of major holdings
16/5/202214:05UKREGCellular Goods PLC Second Price Monitoring Extn
16/5/202214:00UKREGCellular Goods PLC Price Monitoring Extension
12/5/202214:47ALNCIN BRIEF: Cellular Goods promotes new chair; hires former P&G exec
12/5/202207:02UKREGCellular Goods PLC Board changes
28/4/202207:01UKREGCellular Goods PLC First patent application filed
More Cellular Goods News
Cellular Goods Investors    Cellular Goods Takeover Rumours

Cellular Goods (CBX) Discussions and Chat

Cellular Goods Forums and Chat

Date Time Title Posts
24/6/202221:07CBX with Charts & News605
06/5/202208:23Cellular goods consumer cannabis1,023
17/5/202106:36Share Tip Buddy -
26/4/202115:56New gambling stock126

Add a New Thread

Cellular Goods (CBX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2022-06-28 15:35:061.05250,0002,625.00O
2022-06-28 15:25:561.164114.76O
2022-06-28 15:11:091.223,91847.80O
2022-06-28 15:08:381.232563.14O
2022-06-28 14:39:301.234064.98O
View all Cellular Goods trades in real-time

Cellular Goods (CBX) Top Chat Posts

DateSubject
28/6/2022
09:20		Cellular Goods Daily Update: Cellular Goods Plc is listed in the Personal Goods sector of the London Stock Exchange with ticker CBX. The last closing price for Cellular Goods was 1.20p.
Cellular Goods Plc has a 4 week average price of 1.13p and a 12 week average price of 1.13p.
The 1 year high share price is 11.60p while the 1 year low share price is currently 1.13p.
There are currently 507,250,000 shares in issue and the average daily traded volume is 961,294 shares. The market capitalisation of Cellular Goods Plc is £5,833,375.
Read Full Thread
Reply
30/5/2022
07:56		ken chung: "Revenue for the half year to 28 February 2022 amounted to approximately £13k (H1 2021: nil), and a loss before tax of £2.389m was incurred in the period (H1 2021: £2.12m loss)."So just £13k revenue!Current, MCap £8.8, should be below £100k. Expect the share price to drop from 1.5p to 0.015p.Lemmings and mushrooms only.
Read Full Thread
Follow
Reply
12/5/2022
07:35		genierub: Bye bye David Beckham. Look up who David Gardner is. Now you can say bye bye to CBX.
Read Full Thread
Follow
Reply
06/5/2022
08:23		ken chung: CBX MCap should be about £1m not £12m, so share price still to drop 90% or more.Lemmings and mushrooms only.
Read Full Thread
Follow
Reply
13/4/2022
11:23		amran01: II just spoke a piece on CBX in their daily email. It's positive and CBX is getting the attention it has been missing for far too long. This is positive because new money coming in to the stock and it will get pumped
Read Full Thread
Follow
Reply
08/3/2022
11:08		ashleyjv: Cellular Goods (LSE: CBX), a UK-based wellness company that provides premium consumer products formulated with lab-made cannabinoids, announces that on 03, 04 and 07 March 2022, Anna Chokina, Chief Executive Officer of the Company, purchased in aggregate 226,000 ordinary shares in the capital of the Company ("Ordinary Shares") at an average price per share of 3.46 pence. The transactions are Mrs. Chokina's first open market purchases since her appointment on 06 December 2021. The details of the transaction are disclosed below.
Read Full Thread
Follow
Reply
04/3/2022
14:23		currypasty: Cellular Goods (LSE: CBX), a UK-based wellness company that provides premium consumer products based on lab-made cannabinoids, announces that it has issued 2.5 million ordinary shares in the Company ("Ordinary Shares") to satisfy the exercise of warrants. The exercise price is 1p per Ordinary Share. who had the 1p warrants still a profit for them selling today.. you dont convert unless your going to sell them, or they are nearly out of time
Read Full Thread
Follow
Reply
07/12/2021
11:30		whites123: I can assure people that i have zero intention of trying to buy back in as they say. I am openly discussing what I see as many numerous pitfalls of investing in CBX and comparing them to a company that is using Cannabinoids but with medical licenses and potential to do so much good. If you see this as some master plan to buy CBX at a penny less then i think stock investing is the wrong game for you. Read the below: £42 BILLION market is not to be sniffed at.. And that is the market OCTP are targeting. Imperial Brands, Casa Verde as backers LONDON — Oxford Cannabinoid Technologies (OCTP), which enjoys backing from rapper Snoop Dogg and tobacco giant Imperial Brands, launched Friday on the London Stock Exchange. The British company, which specializes in pain-alleviating cannabinoid drug development, raised gross proceeds of £16.5 million ($23.4 million) in its initial public offering, with a starting market value of just over £48 million ($69.1 million). The share price hovered at around 5 pence at midday Friday, after opening near 8 pence. Snoop Dogg, real name Calvin Broadus Jr., has invested in multiple cannabis start-ups including OCT through his venture capital firm Casa Verde. His firm has also backed plant-based food companies such as Outstanding Foods and tech names like Klarna, Robinhood and Reddit. Cannabinoids are naturally occurring compound chemicals found in the cannabis sativa plant and are commonly used for medicinal purposes to treat symptoms such as chronic pain. Oxford Cannabinoid CEO: We want to get our product into the hands of physicians and patients OCTP’s strategy is to develop cannabinoid pharmaceuticals for the nonaddictive treatment of pain conditions. CEO John Lucas told CNBC on Friday the company plans to use the proceeds of its IPO to develop four new drugs. “The key here is about getting cannabinoids into the hands of patients, and the way you do that is through the drug development process,” Lucas told CNBC’s “Squawk Box Europe.” “The medical cannabis, the problem with that is that physicians cannot prescribe it, so we want a drug product that we can get into the hands of physicians, into the hands of patients.” In its listing announcement, OCTP said its “primary market focus is the total addressable pain market, which is estimated to be worth at least £42.5 billion
Read Full Thread
Follow
Reply
02/12/2021
10:05		whites123: having held at a paper loss for months, i sold out 900,000 shares yesterday absorbing a loss of some £27,000 i sincerely hope that it comes good, but after having so much hope and support for cbx the offering, the packaging, the lack of advertising suggest to me it just will not survive in a market of cbd goods that is growing exponentially. the price range is in the medium zone, yet the packaging suggests it as obtained at a 50p stall on a flea market. the market place for these goods is saturated to overflowing point. handpickedcbd.co.uk has so many companies touting these similar products that there is absolutely nothing at all to warrant the higher price being charged by cbx. OCTP: Oxford Cannabinoid flipside of the coin, an where i added some shares yesterday (Another 2 million shares added making my holding 5 million) was OCTP. a company that has a medical license granted for cannabinoid products. not just cbd but specialist medical license. targeting real life needs for pain relief, and the medicinal market. share holders like FTSE 100 British multinational tobacco company Imperial Brands Ventures Limited which holds 10% today directors who are on at best mediocre pay packages dipped their hands into their own pockets to buy shares. yesterday the US OTC listing which will improve liquidity. The clear out of old advisors to be replaced by the excellent harbor access. and still the price is 50% of the IPO listing price. i had to make the decision. what do i think will do best. targeting medical issues like pain from cancer or appealing to face cream markets with products that resemble 50p bottles of moisturising creams. I hope I have made the right decisions and may look in on cbx to see if its still here in a year.
Read Full Thread
Follow
Reply
01/12/2021
08:58		whites123: CBX is a great one.. I hold CBX, but I also hold OCTP and 2 RNS in the space of hours. I did implore you guys to research OCTP. From the pitiful rise it looks like majority of you did not. Masses of opportunity still. Its still 50% less than IPO price.. Last nights RNS was welcomed. This mornings RNS was expected. Both fantastic news. Clear out of old advisors who having overseen the IPO listing have watched the shares fall to less than 50% of that IPO price.. Brilliant news. A few weeks ago the appointment of North American advisors "Harbor Access" A clear out of old dead wood (Non Exec Director) New partnerships.. A rebound to well above 5p (8 to 9p) just to put it on even par with subsequent cannabinoid listings. Except, OCTP has the attention of everyone because it deals with pain relief in those with awful diseases such as cancer.... The Americans will now be able to trade this stock and with Harbor Access doing the PR i foresee this rocketing in the next few months to an share price and MC of a company more worthy of a 10 bagger price.
Read Full Thread
Follow
Reply
29/11/2021
13:13		whites123: n0rbie, I would recommend researching OCTP if you have an interest in cannabinoids providing pain relief for diseases including cancer Agreements with top scientific bodies. Great shareholder base, means likely no requirement to need to go to market for funding. OTC listing in the States very soon. Less than 50% of IPO Clear out of Directors and Non Exec to ensure full alignment and focus on future. One could and should research any of the above. The announcement of researching pain relief in Oncology (Cancer) is welcomed by millions the globe over. Who doesnt know someone who has cancer and benefits from the pain relief THC provides? The share price has been smashed because of the liquidity. Today just small share purchases and the share price rockets. Stick a Million or more shares away for the kids and the likelihood is in a few years time they will never have to work a day in their lives. 10 bagger is more likely to be replaced with 100 bagger if just one of the cannabinoids show to work, and we KNOW they work.. Cannabis works for pain.. we know it does, now we just need the scientific proof and its availability to all.
Read Full Thread
Follow
Reply
Cellular Goods share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
CBX
Cellular G..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220629 04:16:35